Table 1.

Summary of biologics in development for the treatment of eosinophil associated disorders

Target	Drug	Mechanism of Action	Status*
IL-5	Mepolizumab SB-240563	• Block IL-5	• Submitted to FDA and EMA for asthma in November 2014
			• Ongoing trials in asthma, COPD, HES, EoE, EGPA, nasal polyposis and eosinophilic cystitis
	Reslizumab SCH55700		• Phase 3 trials in asthma and EoE completed and open-label extension ongoing
IL-5Rα	Benralizumab MEDI-563	• Inhibits IL-5 binding to receptor	• Ongoing trials in asthma, COPD and HES
		• Depletes eosinophils through enhanced ADCC
CCL-11	Bertilimumab	• Blocks CCL-11	• Not yet recruiting in ulcerative colitis and bullous pemphigoid; planned in asthma
Siglec-8		• Induces eosinophil apoptosis	• In pre-clinical development
EMR1		• Depletes eosinophils through enhanced ADCC	• In pre-clinical development
IgE	Omalizumab Xolair®	• Blocks IgE	• Approved by FDA and EMA for asthma in June 2013 and for chronic idiopathic urticaria in March 2014
			• Ongoing trials in mastocytosis, chronic urticaria, asthma, AERD, nasal polyposis, EoE, eosinophil gastroenteritis, and hyper IgE syndrome
IL-4Rα/IL-13Rα1	Dupilumab REGN668 AMG 317	• Inhibit binding of IL4 and/or IL13 to IL4Rα	• Ongoing trials in asthma, nasal polyposis, atopic dermatitis and ulcerative colitis • Ongoing trials in asthma
IL-13	Lebrikizumab MILR1444A	• Block IL-13	• Ongoing trials in asthma and idiopathic pulmonary fibrosis
	Tralokinumab CAT-354		• Ongoing trials in asthma, ulcerative colitis and idiopathic pulmonary fibrosis
	GSK679586		• Ongoing trials in asthma
	Anrukinzumab IMA638		• Ongoing trials in ulcerative colitis
	AMG 317 QAX576		• Ongoing trials in asthma
			• Ongoing trial in asthma, idiopathic pulmonary fibrosis, EoE, Crohn's Disease and allergic rhinitis
IL-4/IL-13	QBX258 VAK694 +QAX576	• Block both IL-4 and IL-13	• Ongoing trials in asthma
	SAR156597 Bispecific antibody		• Ongoing trial in idiopathic pulmonary fibrosis
TSLP	AMG 157 MEDI9929	• Blocks TSLP	• Ongoing trials in asthma and atopic dermatitis
IL-17Rα	Brodalumab	• Inhibits IL-17A, IL-17F and IL-25 binding to receptor	• Ongoing trials in asthma and psoriasis

ADCC, Antibody-dependent cell-mediated cytotoxicity; AERD, aspirin-exacerbated respiratory disease; COPD, chronic obstructive pulmonary disease; EMA, European Medicines Agency; FDA, Food and Drug Administration.

^*Based on data from clinicaltrials.gov and clinicaltrialsregister.eu as of January 13, 2015.